Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Adult women (>=18 years).
Diagnosed with gynecological tumors (any location and stage).
Previously treated with radiotherapy and/or chemotherapy.
Must accept and sign the specific informed consent for this study.
Not meeting all inclusion criteria.
Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota.
Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results.
Unwillingness or inability to provide written informed consent for study participation.
Patients with gynecological tumors treated with RT and/or CT with or without chronic pelvic toxicity (TPIRQT).
Case-control
Prospective
Not listed
Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups
Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT.
Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.
Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing.
Correlation of gut microbiome profile with grade of pelvic toxicity.
Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data.
Correlation of gut microbiome profile with health-related quality of life (HRQoL).
HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data.
Correlation of gut microbiome profile with anxiety and depression levels.
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data.
Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.
Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition.
Click on the lead sponsor to view all of their trials.
Bernardino Clavo, MD, PhD
Lead sponsor
Hospital Universitario de Gran Canaria Doctor Negrín
Sponsor institution
Hospital Universitario de Gran Canaria Doctor Negrín
Collaborator
Complejo Hospitalario Universitario Insular Materno Infantil
Collaborator
Fundación Canaria Instituto de Investigación Sanitaria de Canarias
Collaborator
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna
Collaborator
Centers for International Business Education and Research
Collaborator
